Biovac secures $15m loan from AfDB for vaccine manufacturing

• The African Development Bank Group has finalized a loan of up to US$15 million to Biovac to support the construction of a new multi-vaccine manufacturing facility in Cape Town.
• Biovac is expected to become Africa's first end-to-end producer of oral cholera vaccines, with plans to subsequently produce vaccines for polio, pneumonia, and meningitis.
• The project aims to increase Biovac's total annual manufacturing capacity to as many as 500 million vaccine doses by 2028.

To address this issue, African leaders have committed to increasing local vaccine manufacturing capacity, with Biovac's expansion being a key part of this effort.

The African continent has set its sights on becoming more self-sufficient in vaccine production, with a goal of producing 60% of the vaccines used locally by 2040. This ambition is driven by the stark reality that Africa currently imports over 99% of its vaccines, despite carrying a disproportionate share of the world's vaccine-preventable disease burden. The continent's reliance on imported vaccines has left it vulnerable to supply chain disruptions and inequities in access to life-saving medicines. To address this issue, African leaders have committed to increasing local vaccine manufacturing capacity, with Biovac's expansion being a key part of this effort.

The Biologicals and Vaccines Institute of South Africa (Biovac) is at the forefront of Africa's vaccine manufacturing ambitions. The company has secured a loan of up to US$15 million from the African Development Bank Group (AfDB) to support the construction of a new multi-vaccine manufacturing facility in Cape Town. This investment will enable Biovac to become Africa's first end-to-end producer of oral cholera vaccines, with plans to subsequently produce vaccines for polio, pneumonia, and meningitis. The project is expected to increase Biovac's total annual manufacturing capacity to as many as 500 million vaccine doses by 2028.

While the US$15 million loan from the AfDB may seem modest in comparison to Africa's vast health needs, its significance extends far beyond its dollar value. The investment is a critical step towards building Africa's health sovereignty and strengthening regional value chains. By supporting local vaccine manufacturing capacity, the AfDB is helping to address the continent's long-standing reliance on imported vaccines and creating industrial capabilities that will enable Africa to respond more effectively to future health crises.

Lawyers and compliance officers should watch for the practical implications of increased local vaccine manufacturing on regulatory frameworks, intellectual property rights, and supply chain management in Africa.

Source: Original reporting via The Independent